@article{6b083bc6f86b47488aaafe04f80d0294,
title = "Aprocitentan: New insights",
keywords = "ACT-132577, PRECISION, aprocitentan, blood pressure, clinical trial, endothelin, hypertension, resistant hypertension",
author = "Fahimeh Varzideh and Urna Kansakar and Jankauskas, {Stanislovas S.} and Gaetano Santulli",
note = "Funding Information: The Santulli's Lab was supported in part by the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI: R01-HL164772, R01-HL159062, R01-HL146691, and T32-HL144456), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK: R01-DK123259 and R01-DK033823) to GS, National Center for Advancing Translational Sciences (NCATS: UL1TR002556-06) to GS, the Diabetes Action Research and Education Foundation (to GS), and the Monique Weill-Caulier and Irma T. Hirschl Trusts (to GS). FV, SSJ, and UK is supported in part by a postdoctoral fellowship of the American Heart Association (AHA-22POST995561, AHA-21POST836407, and AHA-23POST1026190). ",
year = "2022",
month = dec,
day = "22",
doi = "10.3389/fcvm.2022.1093406",
language = "English (US)",
volume = "9",
journal = "Frontiers in Cardiovascular Medicine",
issn = "2297-055X",
publisher = "Frontiers Media S. A.",
}